38 related articles for article (PubMed ID: 1718912)
1. High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma.
Ghods R; Ghahremani MH; Madjd Z; Asgari M; Abolhasani M; Tavasoli S; Mahmoudi AR; Darzi M; Pasalar P; Jeddi-Tehrani M; Zarnani AH
Cancer Immunol Immunother; 2014 Dec; 63(12):1319-27. PubMed ID: 25186610
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker.
Zainodini N; Abolhasani M; Mohsenzadegan M; Farajollahi MM; Rismani E
J Cancer Res Clin Oncol; 2024 Mar; 150(3):165. PubMed ID: 38546751
[TBL] [Abstract][Full Text] [Related]
3. Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.
Yahya MS; Abdel Hameed FF; Radwan NH; Abdelgawad IA; Soliman AF
Asian Pac J Cancer Prev; 2024 Feb; 25(2):709-717. PubMed ID: 38415559
[TBL] [Abstract][Full Text] [Related]
4. Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
Fuhrman-Luck RA; Loessner D; Clements JA
EJIFCC; 2014 Oct; 25(3):269-81. PubMed ID: 27683474
[TBL] [Abstract][Full Text] [Related]
5. Kallikreins - The melting pot of activity and function.
Kalinska M; Meyer-Hoffert U; Kantyka T; Potempa J
Biochimie; 2016 Mar; 122():270-82. PubMed ID: 26408415
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.
Terada N; Shiraishi T; Zeng Y; Aw-Yong KM; Mooney SM; Liu Z; Takahashi S; Luo J; Lupold SE; Kulkarni P; Getzenberg RH
J Cell Biochem; 2014 Sep; 115(9):1505-15. PubMed ID: 24604720
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.
Chadha KC; Nair BB; Chakravarthi S; Zhou R; Godoy A; Mohler JL; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2011 Nov; 71(15):1680-90. PubMed ID: 21446007
[TBL] [Abstract][Full Text] [Related]
8. Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer.
Schmitz MD; Padula GD; Chun PY; Davis AT
Radiat Oncol; 2010 Sep; 5():80. PubMed ID: 20846422
[TBL] [Abstract][Full Text] [Related]
9. Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions.
Satheesh Babu AK; Vijayalakshmi MA; Smith GJ; Chadha KC
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(2):227-35. PubMed ID: 18083072
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
Bindukumar B; Schwartz SA; Nair MP; Aalinkeel R; Kawinski E; Chadha KC
Neoplasia; 2005 Mar; 7(3):241-52. PubMed ID: 15799824
[TBL] [Abstract][Full Text] [Related]
11. Total protein and acid phosphatase concentrations in prostatic fluid from patients with BPH compared to carcinoma.
Kim ED; Smith ND; Grayhack JT
Int Urol Nephrol; 1998; 30(4):471-9. PubMed ID: 9821051
[TBL] [Abstract][Full Text] [Related]
12. A novel approach to the characterization of whole prostate pathology in glycol methacrylate.
Monger LE; Nagabhushan M; Pretlow TG; Pretlow TP
Am J Pathol; 1994 Jul; 145(1):54-60. PubMed ID: 8030756
[TBL] [Abstract][Full Text] [Related]
13. Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.
Berner A; Nesland JM; Waehre H; Silde J; Fosså SD
Br J Cancer; 1993 Aug; 68(2):380-4. PubMed ID: 7688548
[TBL] [Abstract][Full Text] [Related]
14. The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor.
von der Kammer H; Jurincic-Winkler C; Horlbeck R; Klippel KF; Pixberg HU; Scheit KH
Urol Res; 1993 May; 21(3):227-33. PubMed ID: 7688168
[TBL] [Abstract][Full Text] [Related]
15. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
Oosterom R; Bogdanowicz J; Schröder FH
Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
[TBL] [Abstract][Full Text] [Related]
18. The effects of transurethral prostatectomy on serum prostate specific antigen.
Vesey SG; Goble NM; Stower MJ; Hammonds JC; Smith PJ
Br J Urol; 1988 Oct; 62(4):347-51. PubMed ID: 2461243
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
Mulders TM; Bruning PF; Bonfrer JM
Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
